JPH11510488A5 - - Google Patents

Info

Publication number
JPH11510488A5
JPH11510488A5 JP1997506919A JP50691997A JPH11510488A5 JP H11510488 A5 JPH11510488 A5 JP H11510488A5 JP 1997506919 A JP1997506919 A JP 1997506919A JP 50691997 A JP50691997 A JP 50691997A JP H11510488 A5 JPH11510488 A5 JP H11510488A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997506919A
Other languages
English (en)
Japanese (ja)
Other versions
JP4174563B2 (ja
JPH11510488A (ja
Filing date
Publication date
Priority claimed from US08/505,606 external-priority patent/US5925351A/en
Application filed filed Critical
Publication of JPH11510488A publication Critical patent/JPH11510488A/ja
Publication of JPH11510488A5 publication Critical patent/JPH11510488A5/ja
Application granted granted Critical
Publication of JP4174563B2 publication Critical patent/JP4174563B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP50691997A 1995-07-21 1996-07-19 免疫学的疾患の処置のための治療剤としての可溶性リンホトキシン−βレセプターならびに抗リンホトキシンレセプターおよびリガンド抗体 Expired - Fee Related JP4174563B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/505,606 1995-07-21
US08/505,606 US5925351A (en) 1995-07-21 1995-07-21 Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
PCT/US1996/012010 WO1997003687A1 (en) 1995-07-21 1996-07-19 SOLUBLE LYMPHOTOXIN-β RECEPTORS AND ANTI-LYMPHOTOXIN RECEPTOR AND LIGAND ANTIBODIES, AS THERAPEUTIC AGENTS FOR THE TREATMENT OF IMMUNOLOGICAL DISEASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2007161925A Division JP2007254488A (ja) 1995-07-21 2007-06-19 免疫学的疾患の処置のための治療剤としての可溶性リンホトキシン−βレセプターならびに抗リンホトキシンレセプターおよびリガンド抗体

Publications (3)

Publication Number Publication Date
JPH11510488A JPH11510488A (ja) 1999-09-14
JPH11510488A5 true JPH11510488A5 (enExample) 2004-08-26
JP4174563B2 JP4174563B2 (ja) 2008-11-05

Family

ID=24011046

Family Applications (3)

Application Number Title Priority Date Filing Date
JP50691997A Expired - Fee Related JP4174563B2 (ja) 1995-07-21 1996-07-19 免疫学的疾患の処置のための治療剤としての可溶性リンホトキシン−βレセプターならびに抗リンホトキシンレセプターおよびリガンド抗体
JP2007161925A Withdrawn JP2007254488A (ja) 1995-07-21 2007-06-19 免疫学的疾患の処置のための治療剤としての可溶性リンホトキシン−βレセプターならびに抗リンホトキシンレセプターおよびリガンド抗体
JP2011209921A Withdrawn JP2012041350A (ja) 1995-07-21 2011-09-26 免疫学的疾患の処置のための治療剤としての可溶性リンホトキシン−βレセプターならびに抗リンホトキシンレセプターおよびリガンド抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007161925A Withdrawn JP2007254488A (ja) 1995-07-21 2007-06-19 免疫学的疾患の処置のための治療剤としての可溶性リンホトキシン−βレセプターならびに抗リンホトキシンレセプターおよびリガンド抗体
JP2011209921A Withdrawn JP2012041350A (ja) 1995-07-21 2011-09-26 免疫学的疾患の処置のための治療剤としての可溶性リンホトキシン−βレセプターならびに抗リンホトキシンレセプターおよびリガンド抗体

Country Status (28)

Country Link
US (6) US5925351A (enExample)
EP (2) EP1488799A3 (enExample)
JP (3) JP4174563B2 (enExample)
KR (2) KR100493980B1 (enExample)
CN (3) CN1895670A (enExample)
AT (1) ATE279205T1 (enExample)
AU (1) AU715407B2 (enExample)
BG (1) BG63330B1 (enExample)
BR (1) BR9609716A (enExample)
CA (1) CA2227477A1 (enExample)
CZ (1) CZ298277B6 (enExample)
DE (1) DE69633624T2 (enExample)
DK (1) DK0840616T3 (enExample)
EA (3) EA005734B1 (enExample)
EE (1) EE04419B1 (enExample)
ES (1) ES2225889T3 (enExample)
FI (1) FI980122L (enExample)
HU (1) HU227508B1 (enExample)
MX (1) MX9800624A (enExample)
NO (2) NO327163B1 (enExample)
NZ (2) NZ503818A (enExample)
PL (1) PL186911B1 (enExample)
PT (1) PT840616E (enExample)
RO (1) RO121799B1 (enExample)
SI (1) SI0840616T1 (enExample)
SK (1) SK286409B6 (enExample)
TR (1) TR199800091T1 (enExample)
WO (1) WO1997003687A1 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
WO1998017313A2 (en) * 1996-10-25 1998-04-30 Biogen, Inc. Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
EP1723967A3 (en) * 1996-10-25 2007-01-10 Biogen Idec MA, Inc. Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
ES2289778T3 (es) * 1997-04-18 2008-02-01 Biogen Idec Ma Inc. Proteinas de fusion de la region constante de la inmunoglobulina/receptor tgf-beta tipo ii.
US7118742B2 (en) * 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
CZ301026B6 (cs) * 1998-01-30 2009-10-14 Biogen Idec Ma Inc. Použití kompozice inhibující interakci LT-ß a jeho receptoru pro výrobu prípravku k lécení folikulárního lymfomu
IL142284A0 (en) * 1998-10-09 2002-03-10 Biogen Inc A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
HK1047045A1 (zh) * 1999-06-28 2003-02-07 Abbott Gmbh & Co. Kg 預防腫瘤生長的方法
US6346247B1 (en) 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
TR200300478T2 (tr) * 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
WO2002083162A1 (en) * 2001-04-13 2002-10-24 University Of Chicago Use of a cd8+ t cell inhibitory agent in the presence of a cd4+ t cell inhibitory agent for inhibition of transplant rejection
US7265208B2 (en) * 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
WO2003011322A1 (en) * 2001-08-02 2003-02-13 Genset S.A. Agonists and antagonists of genoxin for use in the treatment of metabolic disorders
US7273707B2 (en) * 2002-02-08 2007-09-25 Wyeth Method of identifying a modulator of a LTβR complex signaling pathway
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
EP1565214A2 (en) * 2002-10-31 2005-08-24 Biogen Idec MA Inc. Treatment of immunological renal disorders by lymphotoxin pathway inhibitors
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
RS20050481A (sr) * 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
WO2005067477A2 (en) * 2003-12-08 2005-07-28 Centocor, Inc. Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
BRPI0509201A (pt) * 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
ZA200701484B (en) * 2004-08-03 2008-07-30 Biorexis Pharmaceutical Corp Combination therapy using transferrin fusion proteins comprising GLP-1
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2006135660A2 (en) * 2005-06-10 2006-12-21 University Of Chicago Therapies involving lymphotoxin beta receptor
CA2624730A1 (en) * 2005-10-04 2007-04-12 The John Hopkins University Compositions and methods for treating inflammation
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
KR101193722B1 (ko) * 2006-07-24 2013-01-11 바이오렉시스 파마슈티칼 코포레이션 엑센딘 융합 단백질
NZ576032A (en) * 2006-10-12 2012-03-30 Genentech Inc Antibodies to lymphotoxin-alpha
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
SG178002A1 (en) * 2006-10-20 2012-02-28 Biogen Idec Inc Treatment of demyelinating disorders
CN111518218A (zh) 2006-11-02 2020-08-11 阿塞勒隆制药公司 Alk1受体和配体拮抗剂及其用途
US8440185B2 (en) 2006-12-26 2013-05-14 The Johns Hopkins University Compositions and methods for the treatment of immunologic disorders
CN101951940A (zh) * 2007-03-15 2011-01-19 比奥根艾迪克Ma公司 自身免疫病的治疗
MX2009013410A (es) 2007-06-08 2010-03-22 Biogen Idec Inc Biomarcadores para predecir capacidad de respuesta anti-tnf o sin capacidad de respuesta.
EP2382238A1 (en) * 2008-12-31 2011-11-02 Biogen Idec MA Inc. Anti-lymphotoxin antibodies
JP6952685B2 (ja) 2015-06-05 2021-10-20 アイバイオ・インコーポレイテッドＩｂｉｏ， Ｉｎｃ． 線維症の治療において使用するためのエンドスタチン断片およびバリアント
WO2019238966A1 (en) * 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
EP3969569A1 (en) 2019-05-14 2022-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Regulatory t cells targeted by lymphotoxin alpha blocking agent and uses thereof
EP4392455A4 (en) 2021-08-25 2025-08-20 Ibio Inc ANTI-CD-25 ANTIBODIES

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4338397A (en) * 1980-04-11 1982-07-06 President And Fellows Of Harvard College Mature protein synthesis
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4758549A (en) * 1983-12-13 1988-07-19 Kabushiki Kaisha Mayashibara Seibutsu Kagaku Kenkyujo Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses
NZ212207A (en) * 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
US4959457A (en) * 1984-05-31 1990-09-25 Genentech, Inc. Anti-lymphotoxin
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
CA2001756A1 (en) 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
ES2157889T3 (es) * 1990-06-27 2001-09-01 Biogen Inc Linfotoxina complejada de superficie.
US7030080B2 (en) * 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5795964A (en) * 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
AU692146B2 (en) * 1990-06-27 1998-06-04 Biogen Idec Ma Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5747023A (en) 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
WO1996022788A1 (en) 1995-01-26 1996-08-01 Biogen, Inc. LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS
GB9514518D0 (en) 1995-07-15 1995-09-13 Sod Conseils Rech Applic Guanidine salt inhibitors of NO synthase and cyclooxygenase
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
US7255854B1 (en) * 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
WO1998017313A2 (en) 1996-10-25 1998-04-30 Biogen, Inc. Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
CA2229449A1 (en) 1997-04-25 1998-10-25 Takeda Chemical Industries, Ltd. Novel receptor protein and its use
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
IL142284A0 (en) * 1998-10-09 2002-03-10 Biogen Inc A pharmaceutical composition containing an agent which blocks the binding of lymphotoxin-b to its receptor
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
TR200300478T2 (tr) * 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
EP1539793A4 (en) * 2002-07-01 2006-02-01 HUMANIZED ANTIBODIES AGAINST THE RECEPTOR OF LYMPHOTOXIN BETA
WO2004058191A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
RS20050481A (sr) * 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima
BRPI0509201A (pt) * 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
WO2007146414A2 (en) 2006-06-15 2007-12-21 Biogen Idec Ma Inc. Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents

Similar Documents

Publication Publication Date Title
JP2000500228A5 (enExample)
JP2000500445A5 (enExample)
JP2000500440A5 (enExample)
JP2000500033A5 (enExample)
JPH11506662A5 (enExample)
JPH11511015A5 (enExample)
JP2000500327A5 (enExample)
JPH11514350A5 (enExample)
JP2000500145A5 (enExample)
JP2000500155A5 (enExample)
JP2000500406A5 (enExample)
JP2000500361A5 (enExample)
JP2000500322A5 (enExample)
JP2000500258A5 (enExample)
JP2000500342A5 (enExample)
JP2000500192A5 (enExample)
JP2000500112A5 (enExample)
JP2000500051A5 (enExample)
JP2000500407A5 (enExample)
JP2000500166A5 (enExample)
JP2000500397A5 (enExample)
JP2000500019A5 (enExample)
JP2000500125A5 (enExample)
JP2000500044A5 (enExample)
JP2000500346A5 (enExample)